Grantham Mayo Van Otterloo & Co. LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Grantham Mayo Van Otterloo & Co. LLC trimmed its stake in Regeneron by 5.8% in Q3, selling 3,809 shares and ending the quarter with 61,474 shares worth about $34.57 million (≈0.06% of the company).
• Several large institutions moved in the quarter—State Street, Dodge & Cox, Franklin Resources and Loomis Sayles all increased positions, and Norges Bank opened a new roughly $628 million position—leaving institutional ownership at about 83.31%.
• Analysts rate Regeneron as a Moderate Buy with a consensus price target of $802.27; the company recently beat Q4 estimates (EPS $11.44 vs $10.74, revenue $3.88B vs $3.76B) and raised its quarterly dividend to $0.94 (annual $3.76, yield ~0.5%).

Grantham Mayo Van Otterloo & Co. LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 61,474 shares of the biopharmaceutical company's stock after selling 3,809 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC owned about 0.06% of Regeneron Pharmaceuticals worth $34,565,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in REGN. State Street Corp lifted its holdings in Regeneron Pharmaceuticals by 0.9% during the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company's stock valued at $2,536,801,000 after purchasing an additional 42,343 shares in the last quarter. Dodge & Cox increased its stake in shares of Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company's stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company's stock valued at $1,214,585,000 after purchasing an additional 36,821 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company's stock valued at $1,019,062,000 after purchasing an additional 305,089 shares during the period. Finally, Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $628,151,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. HSBC started coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a "buy" rating and a $255.00 price objective for the company. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an "equal weight" rating in a report on Monday, February 2nd. Bank of America raised shares of Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and increased their price objective for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a "buy" rating in a report on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $802.27.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares of the company's stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares of the company's stock, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,274 shares of company stock valued at $4,142,738 over the last quarter. Company insiders own 7.02% of the company's stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $759.82 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The firm has a market capitalization of $80.33 billion, a P/E ratio of 18.28, a price-to-earnings-growth ratio of 2.04 and a beta of 0.41. The company has a fifty day simple moving average of $770.81 and a two-hundred day simple moving average of $688.75. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the company earned $12.07 EPS. The business's revenue was up 2.5% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.